GH Research (NASDAQ:GHRS) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of GH Research (NASDAQ:GHRS - Free Report) in a research note published on Wednesday. The brokerage issued an overweight rating and a $25.00 price target on the stock.

Other analysts have also issued research reports about the company. Wall Street Zen lowered GH Research from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of GH Research in a research note on Friday, May 9th. Stifel Nicolaus raised their price objective on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Royal Bank of Canada initiated coverage on GH Research in a report on Friday, March 7th. They set an "outperform" rating and a $31.00 price objective on the stock. Finally, Guggenheim cut their price objective on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, GH Research presently has an average rating of "Moderate Buy" and an average target price of $32.00.

GH Research Stock Performance

GHRS traded up $0.18 on Wednesday, hitting $12.61. 138,491 shares of the company were exchanged, compared to its average volume of 184,054. GH Research has a 12 month low of $6.00 and a 12 month high of $20.50. The company has a market cap of $656.07 million, a PE ratio of -15.96 and a beta of 0.97. The stock's fifty day moving average is $10.32 and its 200-day moving average is $10.21.

GH Research (NASDAQ:GHRS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.42. As a group, equities research analysts expect that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Northern Trust Corp increased its position in GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock valued at $286,000 after buying an additional 8,641 shares in the last quarter. Woodline Partners LP increased its position in GH Research by 112.0% in the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company's stock valued at $553,000 after buying an additional 41,711 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in GH Research in the 4th quarter valued at about $44,000. Lynx1 Capital Management LP increased its holdings in GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock worth $34,013,000 after purchasing an additional 663,100 shares in the last quarter. Finally, Diadema Partners LP bought a new stake in GH Research during the 4th quarter worth approximately $711,000. 56.90% of the stock is owned by institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).